Wells Fargo
ADPT icon

Wells Fargo’s Adaptive Biotechnologies ADPT Stock Holding History

Wells Fargo’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,000
Closed -$114K – 6283
2020
Q2 		$114K Buy
+25,000
New +$912K ﹤0.01% 5166

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo's ADPT Position: Q1 2026 in Review

Wells Fargo reduced its Adaptive Biotechnologies (ADPT) stake by 57% in Q1 2026, selling an estimated $1.73M and leaving 81,795 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3667.

Wells Fargo first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $79.1M in Q4 2020. 296 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Wells Fargo held 81,795 shares of Adaptive Biotechnologies worth $1.14M as of Q1 2026.
  • Wells Fargo sold 108,589 Adaptive Biotechnologies shares in Q1 2026, an estimated $1.73M.
  • Adaptive Biotechnologies made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3667 holding.
  • Wells Fargo first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • Wells Fargo's Adaptive Biotechnologies position peaked at $79.1M in Q4 2020.
  • 296 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.